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Abstract This article discusses dried blood spot (DBS)
sampling in therapeutic drug monitoring (TDM). The most
important advantages of DBS sampling in TDM are the
minimally invasive procedure of a finger prick (home sam-
pling), the small volume (children), and the stability of the
analyte. Many assays in DBS have been reported in the lit-
erature over the previous 5 years. These assays and their
analytical techniques are reviewed here. Factors that may
influence the accuracy and reproducibility of DBS methods
are also discussed. Important issues are the correlation with
plasma/serum concentrations and the influence of hematocrit
on spot size and recovery. The different substrate materials
are considered. DBS sampling can be a valid alternative to
conventional venous sampling. However, patient correlation
studies are indispensable to prove this. Promising develop-
ments are dried plasma spots using membrane and hemato-
crit correction using the potassium concentration.
Key Points
Hematocrit has influence on spot size, recovery, and
blood-to-plasma ratio
Strategies to cope with the hematocrit influence
include avoiding the effect, minimizing the effect, or
measuring hematocrit by means of the determination
of potassium
More attention is needed on the clinical validation of
dried blood spot methods
1 Introduction
Assays of drugs for therapeutic drug monitoring (TDM)
are usually performed in serum or plasma, obtained by
venous blood sampling. However, there is growing
interest in dried blood spot (DBS) sampling in TDM.
Compared with conventional venous blood sampling,
DBS sampling is a convenient and simple sampling
method with better patient comfort. In DBS sampling,
capillary blood is obtained from a finger prick with an
automatic lancet. With clear instructions and after ade-
quate training, patients should be able to do this finger
prick themselves. After disinfection, the patient pricks his/
her finger with a lancet, preferable with an autoretracting
(1.8–2.4 mm) needle. The first blood drop is discarded
because it contains more tissue fluid. The next drop is
collected to fill a premarked circle on a filter paper; one
drop in one circle. The DBS is allowed to dry at room
temperature and then is packed for transportation to the
laboratory. In the laboratory, the homogeneity of the
blood spot is assessed. A disc is punched out from the
blood spot. This disc represents a fixed volume of
absorbed blood, depending upon the disc diameter. After
extraction, the analyte is measured with an analytical
technique. Several methods were published over the pre-
vious 2 years about drug quantification in DBS for anti-
epileptic drugs [1, 2], immunosuppressants [3–6],
antiretrovirals [7–9], cardiovascular therapy [10], psy-
choactive drugs [11, 12], and antibiotics [13–16]. In 2009,
Edelbroek et al. [17] published a review about DBS in
Therapeutic Drug Monitoring. This article discusses the
progress that has been made since then.
DBS sampling has a number of advantages and disad-
vantages over conventional venous sampling.
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The advantages are as follows:
• Easy and minimally invasive sampling. The patients
can perform the finger prick at home, and no phlebot-
omist is necessary. This makes it more convenient to do
abbreviated area under the concentration-time curve
measurements because there is no need for the patient
to wait in the hospital.
• Only a small volume is required. One of the original
projected advantages of using DBS technology is the easy
implementation for small sample volume collection from
finger and heel pricks in young children and neonates.
• Most analytes are more stable in DBS than in frozen
samples [18–21].
• Convenient storage and transport. DBS specimens can
be shipped or transported with no reasonable expecta-
tions of exposure to blood or other infectious material
by handlers and can be sent via normal postal systems
without special mailing cartons [22].
Debate is ongoing as to whether blood is a more represen-
tative matrix than plasma or serum. The fact is that bioanalysis
of most drugs, with the exception of immunosuppresants, is
carried out in plasma or serum and reference values are based
on these matrices. Additional validation is required to translate
capillary blood-to-plasma concentrations.
The disadvantages are as follows:
• Only small volumes are available and therefore a
sensitive analysis technique is required and usually
only one assay per spot can be performed.
• Risk of contamination. If the same person does the
finger prick and the dosing, the risk of contaminating
the filter paper with the drug is possible.
• There is no spare sample.
• Despite adequate training of the patient, the sampling is
not always successful
• Extensive validation is required. The impact of varia-
tions of hematocrit (Hct) values on the spot size and
homogeneity should be understood as well as their
impact on assay performance. The influence of the
spotted blood volume and spot homogeneity should be
studied. Any change in filter paper type and/or man-
ufacturer requires a partial validation [23].
• Capillary concentration can be different from venous
concentration because the material in DBS consists of
blood cells, plasma, and interstitial fluid.
2 Translation of Dried Blood Spot to Plasma Drug
Concentration
The relationship of drug distribution between plasma and
the cellular parts of the blood is important in TDM,
especially when comparing drug concentration in DBS
with reference plasma concentrations. The historical per-
spective for the predominant use of plasma in TDM orig-
inates from early analytical challenges of working with
whole blood: accurate aliquoting, extraction of the ana-
lytes. The distribution of a drug in blood at equilibrium can




Cb ¼ 1  Hct
fu





¼ 1  Hctð Þ þ Hct  q fu ð3Þ
where Cp, Cu, and Cb are total plasma concentration,
unbound concentration, and total blood concentration,
respectively, fu is the unbound fraction and q the
erythrocyte-to-plasma concentration ratio. Thus, total plasma
concentration is directly proportional to Cu when the fu is
constant. The Cb /Cp ratio depends on Hct, unbound fraction
in plasma, and the erythrocyte-to-plasma concentration ratio.
Emmons and Rowland conclude that when variability in
fu and q is low, then either plasma or DBS can be used.
When the blood-to-plasma ratio is close to 0.55, then
variability in fu (and to a lesser extent Hct) becomes a
concern, and an understanding of the inter- and intra-
individual variation in plasma protein binding is required.
However, when the blood-to-plasma ratio is much larger,
especially two or greater, then variability in q becomes the
dominant concern when using DBS [24]. In practice, it is
always necessary to do a clinical validation to translate
DBS to plasma concentration.
3 Hematocrit Effect
Recently, De Kesel et al. [25] published an extensive
review about the effect of Hct on the qualitative analysis of
DBS. The Hct is the volume percentage of red blood cells
in blood and has considerable effect on blood viscosity. It
can have a direct influence on the accuracy and precision of
the analysis of drugs in bioanalytical assays using DBS.
This effect is a result of a complex phenomenon. Vari-
ations in Hct will cause different spreading of the blood in
the DBS paper. This is illustrated in Fig. 1. The Hct effect
is dependent on the chemical and physical properties of the
drug in combination with DBS paper properties [26, 27]. A
relatively low Hct will result in a negatively biased, target
analyte concentration. Ingels et al. [26] reported a 15 %
deviation at Hct = 0.35 and ?10% at Hct = 0.55 com-
pared with the gamma-hydroxybutyric acid concentration
at the normalized Hct of 0.44.
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The recovery rate of a drug can vary with varying Hct:
high recovery at low Hct and low recovery at high Hct
[28]. Koster et al. [6] proved the effect of the concentration
and Hct on the recovery of sirolimus and everolimus.
Depending on differences in physical properties, the
drug might undergo a non-homogeneous distribution
within the DBS sample [28, 29]. Nonhomogeneous distri-
bution of the drug as a result of chromatography on the
paper is also observed with high blood loading volumes
[30]. Furthermore, the Hct has influence on the blood-to-
plasma ratio as illustrated in Eq. 3.
Hematocrit is currently identified as the single most
important parameter influencing the spread of blood on
DBS cards, which could impact the validity of the results
generated by DBS methods, affecting the spot formation,
spot size, drying time, homogeneity, and, ultimately, the
robustness and reproducibility of the assays [23]. It is
therefore remarkable that 10 out of 24 studies in Table 1
did not assess the influence of Hct.
Strategies to cope with the Hct influence can be divided
into avoiding the effect and minimizing the Hct effect.
3.1 Avoiding the Hematocrit Effect
The Hct effect can be avoided by analyzing the entire DBS.
This eliminates the variation from spreading and nonho-
mogeneity [31]. However, this makes accurate volumetric
application the most critical parameter and it will be difficult
to train people not accustomed to the laboratory technique.
Youhnovski et al. presented a modification of the tra-
ditional DBS, named pre-cut dried blood spot (PCDBS).
Paper discs are cut from the filter paper and mounted with
double-sided adhesive tape. The paper discs are spotted
with blood. In contrast to the classical DBS technique, the
PCDBS procedure demonstrates no variation in response,
within ± 3 %, independently of the Hct level or the type of
card used. For quantification of naproxen by liquid chro-
matography/electrospray ionization tandem mass spec-
trometry (LC/ESI-MS/MS), the PCDBS technique was
demonstrated to be as precise (coefficient of variation B3.1
%) and accurate (between 95.4 and 104.4 %) as the clas-
sical DBS procedure [32]. Additionally, the use of PCDBS
can also eliminate sample carryover from the mechanical
punching of conventional DBS samples [33].
Li et al. described the concept of perforated dried blood
spots (PDBS). PDBS discs were prepared from regular
filter paper, with a diameter of 6.35 mm with a single-hole
paper puncher. These discs are spotted with an accurate
amount of blood sample (5–10 lL), dried, and then stored.
Upon sample analysis, PDBS samples are pushed by sin-
gle-use pipette tips into 96-well plates [34].
Meesters et al. presented the dried matrix on paper discs
(DMPD). The precut paper discs were placed in a plastic
cartridge. The sample is loaded with a pipette or a capillary
tube. DMPD eliminated the Hct effect and demonstrated
better accuracy and precision than regular DBS with partial
punching. Observed accuracy and precision were 6.0 and
2.3% for DMPD, respectively, and -10.4 and 17.1%, for
DBS, respectively [35]. However, all these three develop-
ments require volumetric application on DBS. There are
currently no tools available that allow a non-experienced
patient to accurately deposit a fixed volume of blood onto a
paper card. This makes these methods less attractive when
aiming at patient self-sampling.
Dried plasma spots (DPS) can be generated by collect-
ing plasma samples on filter cards. This sampling strategy
requires a longer procedure for sample collection because
of the centrifugation step that is necessary to obtain
plasma. Drug quantification in DPS has been described for
antibiotics [36, 37], antiretrovirals [38], and for gabapentin
[39]. Barfield and Wheller [40] described the analytical
validation of DPS. Because of the centrifugation step,
patient self-sampling is impossible.
Li et al. recently presented a two-layered polymeric
membrane for the formation of separated DPS from whole
blood. Molecular filtration of red blood cells from applied
microsamples of whole blood was accomplished with a
two-layer polymeric membrane substrate. The lower
membrane surface containing the separated plasma spot
was physically separated from the upper membrane and
dried, followed by semi-automated direct elution of the
sample to an online solid-phase extraction cartridge
Fig. 1 Appearance of dried blood spots at different blood Hct levels.
Hct = 0.18 (a); Hct = 0.35 (b); Hct = 0.50 (c). Aliquots of 50 lL
blood were applied to the paper and allowed to dry for 4 h under
ambient conditions in the laboratory. The different Hct levels were
prepared by mixing washed red blood cells and serum. The preprinted
circles are 13 mm in diameter. Hct hematocrit
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followed by liquid chromatography coupled to tandem
mass spectrometry (LC/MS/MS). They applied this method
on the quantitative determination of guanfacine. The
described work demonstrates proof of principle using
membrane sample preparation techniques to form DPS
samples from whole blood for subsequent bioanalysis [41].
The same principle is used by Kim et al. [42] for the
quantification of 25-hydroxy vitamin D in plasma obtained
by a finger prick. This approach has the potential to
eliminate the Hct as well capillary blood-to-plasma issues.
3.2 Minimizing the Hematocrit Effect
The most frequently used method for correction of the Hct
is the standardization of the Hct in the calibration standards
close to the expected Hct of the samples. This is the most
practical and easiest method for correction; calibration
standards are custom prepared and it is therefore easy to
control the Hct. However, sometimes the bias is too large
and a different method for correction has to be used [6, 53,
54, 60, 67, 70].
3.3 Measuring Hematocrit in Dried Blood Spot
Recently, a new method has been proposed for the
assessment of Hct in DBS [43].
It is not possible to measure the hematocrit directly in
DBS and therefore a marker has to be used. Potassium is
mainly present intracellularly, the concentration is about 35
times higher than the extracellular concentration. Because
of this difference and the fact that erythrocytes are the
predominant cells in blood, potassium corresponds well
with the erythrocyte fraction and therefore with the Hct. In
addition, potassium is a stable component. Furthermore,
the inter-individual variation is small and it has a narrow
normal plasma concentration range of 3.6–4.8 mmol/L.
The use of potassium as a marker to calculate the Hct
was studied by Capiau et al. From 111 patients, samples
were collected in EDTA and lithium heparin tubes to
determine the agreement between the Hct in DBS samples
and EDTA whole blood. The Hct in EDTA whole blood
was determined on a Sysmex XE-5000 hematology ana-
lyzer as the reference assay. The lithium heparin whole
blood was used to prepare spots and was analyzed
according to the reported assay. The statistical tests showed
that the agreement is high and that potassium is suitable to
predict the Hct in unknown samples.
It should be noted that the experiment was not per-
formed in capillary blood. The use of anticoagulants, such
as heparin, influences the blood viscosity [44] and therefore
it should be tested in capillary blood. Furthermore, the
implementation of the potassium measurement and the
consecutive correction of the analytical results have not
been tested. In our laboratory, we have performed a similar
test to calculate the Hct, with comparable results. More
importantly, the use of potassium to calculate the Hct and
the following Hct correction was tested for analysis of
creatinine in DBS samples. The results seem to be prom-
ising and the correction enhanced the accuracy signifi-
cantly. These data are currently under submission. To
conclude, the measurement of potassium to calculate the
Hct seems promising and is possibly a tool to correct for
the Hct influence. More research has to be performed to
investigate the implementation of the correction and its use
in routine analysis.
4 Filter Paper
The most used filter papers are Whatman 903, Ahlstrom
226, Whatman FTA DMPK-C, Whatman 31 ET CHR,
Whatman 3, and Agilent Bond Elut DMS (Table 1).
Whatman 903 and Ahlstrom 226 are US Food and Drug
Administration registered for blood collection as class II
medical devices. DMPK cards are developed for mic-
rovolume sampling (10–20 lL) in drug metabolism and
pharmacokinetics studies. DMPK-A and DMPK-B cards
lyse cells and denature protein on contact. DMPK-C cards
are not impregnated with chemicals that potentially inter-
fere with bioanalysis [45].
During method development, some laboratories screen
different card types and solvent mixtures. This approach
allows for the selection of the best combination to facilitate
further method optimization [45]. Sometimes, analytical
results with more than one paper are reported [6, 15, 46–
48]. Luckwell et al. [49] investigated within and between
lot variations for four cellulose paper types: Whatman FTA
DMPK-A, -B, and -C, and 903. The substrates were tested
to demonstrate manufacturing reproducibility (thickness,
weight, chemical coating concentration) and its effect on
the size of the DBS produced, and the quantitative data
derived from the bioanalysis of human DBS samples
containing six compounds of varying physicochemical
properties. Within and between lot variations in paper
thickness, mass, and chemical coating concentration were
within acceptable manufacturing limits. No variation in the
spot size or bioanalytical data was observed. Bioanalytical
results obtained for DBS samples containing a number of
analytes spanning a range of chemical space are not
affected by the lot used or by the location within a lot [49].
Novel substrate material that minimizes the effect of Hct
on spot size and recovery are under investigation.
Recent developments in the filter papers are the non-
cellulose ‘papers’. The Agilent Bond Elut DMS card is an
example of this type of material. This non-cellulose
material is less influenced by the Hct and should perform
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better with LC-MS/MS analysis because of the lack of
cellulose. From the 36 articles mentioned in Table 1, only
three [46, 47, 50] tested this paper, and from those three
only one actually used this material [50]. The other two
articles mentioned poor precision obtained with the non-
cellulose material. Although not published, our laboratory
also tested the material and we found the material to be
fragile and the saturation inconsistent, similar to the find-
ings of Lawson et al. [46]. More recently, another type of
material was tested for DBS sampling: alginate and
chitosan foam by Eibak et al. [51]. This article describes
the synthesis of foam-like material on which the blood can
be spotted. The authors compared this with DMPK and
Agilent Bond Elut DMS using four drugs. The recovery
was higher and the drug extraction was easier to perform
compared with the DMPK and DMS papers. However, the
influence of the Hct was not tested and the drug extraction
was not optimized for the DMPK and DMS papers.
Although the sample preparation seems to be less labori-
ous, more investigation with this material is needed.
5 Internal Standards
Normal application of the internal standard (IS) is addi-
tional in the extraction solvent. Although this is the easiest
manner of application, it is not the right procedure to apply
an IS. As Abu-Rabie et al. described [52], there are several
options to apply the IS, (1) addition to the extraction sol-
vent, (2) treatment of the paper before use, (3) addition of
the IS to the sample before spotting, and (4) application of
the IS on the spot after spotting. In daily practice, options 2
and 3 are not very suitable. Treated paper requires distinct
marking in the case of multiple DBS studies or analysis,
furthermore sufficient data should be available regarding
the stability of the IS when applied to the paper. Addition
of the IS before spotting negates one of the biggest
advantages of DBS sampling, namely that patients can
perform DBS sampling at home. Because of these disad-
vantages, the IS was applied after spotting on the paper
rather than as an addition to the extraction solvent. The
chosen technique was spraying with Touchspray, a device
developed by The Technology Partnership. The spraying of
the IS was well researched on different types of paper
(DMPK-A, DMPK-B, and Ahlstrom 226) and after solving
problems with spray volume it was found to be equally
accurate and precise as addition of the IS to the extraction
solvent. This result was also found by Zimmer et al. [53].
Although a different way of spraying was used, the accu-
racy and precision of the spraying were high. Some opti-
mization can be performed for both methods as the authors
state themselves, but already it seems to be a good alter-
native for IS use. However, it is not clear what
improvement is made in reference to the addition of the IS
via the extraction solvent. As Abu-Rabie et al. showed, the
accuracy and precision were good but no obvious
improvement is presented. The article of Zimmer et al. did
not compare with a reference method.
Addition of the IS in the extraction solvent is not how an
IS should be used, but different methods of application in
DBS sampling have some major disadvantages. The most
promising alternative method of application is spraying the
IS, but more research and optimization is required.
6 Automation
Although DBS sampling has several advantages for
patients, sample handling is significantly increased for
laboratories. Typical sample pretreatment of DBS samples
involves punching, extraction, centrifugation, aliquot
transfer, drying, and dissolution in an appropriate solvent.
Furthermore, the duration of the extraction can be quite
long. Naturally, varieties on this procedure are possible, but
especially compared with protein precipitation of plasma, it
is more laborious. It is therefore not surprising that several
methods for automation have been proposed. Roughly
three categories of automation can be distinguished, on-line
desorption of a DBS sample, paper spray analysis of DBS
samples, and fully automated extraction of DBS samples.
On-line desorption involves the clamping of a DBS card or
punched-out disk and the consecutive extraction with
mobile phase or dedicated extraction solvents [54–56].
This method can be augmented with the addition of on-line
SPE for sample cleanup. In the presented methods of
De´glon and Thomas, good accuracy and precision was
obtained, furthermore it is partly automated. The disad-
vantage of the presented method is the need for manual
punching and the large diameter. It is our experience that in
daily use it is difficult to obtain regular-shaped spots with
the same sample volume. The large diameter makes it
difficult to punch out a part of the DBS sample and when
using the complete DBS it is necessary to determine the
spotted volume.
Extraction of drugs from DBS cards with paper spray is
the ionization of drugs directly from paper substrates.
Briefly, a piece of paper is placed in front of the MS
entrance and wetted with appropriate solvents. After wet-
ting, an electric potential is applied to the paper that ionizes
the drugs and migrates the drugs to the entrance of the MS
detector [57–59]. One of the greatest advantages of this
method is the speed of analysis; in mere minutes, drugs are
extracted and analyzed. Additionally, low volumes of
organic solvent are needed and no analytical column is
required. The disadvantage of this method is the need to cut
paper into triangular shapes, as similar to the on-line
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desorption method it is necessary to determine the spotted
blood volume before analysis. The third category is full
automation of the DBS analysis. Barcode-marked DBS
samples are placed in a robot that performs all steps
automatically. Methods are reported with on-line desorp-
tion [60] and a nano-electrospray platform [61]. The
automated on-line desorption method showed better ana-
lyte response and required little organic solvent. However,
some issues were mentioned regarding leakage and
extraction recovery. The nano-electrospray method
required little organic solvent and the analysis time was
short. However, at the lower concentrations, the precision
and accuracy increased rapidly.
Development of automated DBS analysis is likely to
increase quickly; sample preparation of DBS samples is
often more laborious than for plasma or blood. Automation
can reduce analysis time, the use of organic solvents, and
sample preparation time. However, the costs of robotic
sample handlers can be quite high and more research has to
be done. The majority of the reported methods are only
tested in a controlled laboratory environment, with per-
fectly shaped DBS samples and known blood volumes. In
daily routine analysis, more deviation in shape, volume,
and Hct is expected; robotic sample handlers should be
able to control these deviations.
7 Validation
Analysis of blood or plasma samples is daily practice and
consequently the validation of the analytical methods. The
analysis of DBS samples is, compared with blood and
plasma samples, relatively new and less information was
available on method validation. During the previous few
years, this information has grown and this resulted in a
guideline released by the European Bioanalysis Forum
(EBF) [23] In short, testing the influence of hemolysis,
anticoagulants, homogeneity of the sample, carry over,
extraction recovery, multiple punches from a spot, stability,
and good blood spotting practices (GBSP) is recom-
mended. As can be seen in Table 1, several of the proposed
validation parameters are tested regularly. The influence of
HCT was validated in 39 % of the cited articles and the
blood volume in 45 %. The punch location was tested by
13 % of the research groups and only one validated the spot
homogeneity. The term GBSP is a direct analog to the GxP
guidelines and is introduced by the EBF to show the
importance of the quality of the blood spotting. This is a
difficult parameter to validate, because most mentioned
problems with GBSP are introduced when patients take the
sample at home. In a laboratory setting or other controlled
environment, it is much easier to control the spotting
procedure.
8 Proficiency Testing for DBS Samples
There is no proficiency testing programs for TDM by DBS.
The different types of matrices complicate the design of
such a program. The Association for Quality Assessment in
Therapeutic Drug Monitoring and Clinical Toxicology
(KKGT, the Netherlands) is currently studying the poten-
tial for a proficiency testing program for DBS samples.
9 Review of Methods Published in the Previous 5 Years
Table 1 provides an overview of drugs for which TDM
using the DBS method has been reported in the literature in
the previous 5 years. The analyte concentrations in DBS
are measured by the application of various quantitative
analytical techniques, including GC-MS [62], HPLC-UV
[63], HPLC fluorimetry [64], LC-MS/MS [65], and
immunoassays [66]. The assay ranges indicated, however,
seemed sufficient for TDM for almost all drugs; very
specific and sensitive methods (e.g., LC-MS/MS) seem to
be preferable. HPLC-DAD is applicable in the mg/L range
[1, 67–69].
Sampling was performed using two methods: the first
method (A) involves the sampling of a drop of whole blood
directly on the sampling paper within a premarked circle,
and the second method (B) requires accurately pipetting
capillary blood with a pipette on sampling paper. In
method A, a paper disc is punched out from the DBS with a
smaller diameter than the blood spot itself. The punching
technique must be reproducible, and a special punching
apparatus is necessary [70]. The disc represents a volu-
metric measurement comparable to a liquid measurement.
The use of various brands of sampling paper is described in
the publications, but the precise nature of the paper is not
always mentioned [71].
In nearly all papers, the analytical validation seems ade-
quate in terms of the current standards as described in the
guideline on bioanalytical method validation [72]. However,
the impact of variations of Hct values, spotted blood volume,
and spot homogeneity are lacking in many articles.
Clinical validation is sometimes lacking in the articles,
considering genuine clinical validations to be comparisons
of concentrations found in venous samples and DBS sam-
ples, taken at the same time, and consecutive statistical
analysis. In some papers, however, no comparison with
venous sampling was made or only a few concentration-time
curves, constructed with DBS samples, are presented.
Sometimes a form of ‘‘in vitro’’ validation was performed:
DBS samples were produced in vitro in the laboratory with
the help of venous whole blood samples from humans.
Concentrations, measured in these DBS samples, were then
compared with concentrations found in the original whole
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blood samples. We have scored this as a limited validation.
The stability of medicines in DBS samples during storage
was studied in most of the articles in Table 1. Most analytes
investigated in the DBSs were reported to be fairly stable.
10 Discussion
The standardization of the DBS technique that Edelbroek
et al. [17] advocated in 2009 is not materialized. Whole spot
cutting, pre-cut spots, and DPS are new developments in the
previous 5 years. There are two areas in TDM where the
DBS technique has significant advantages: home sampling
by the patient and TDM in infants and neonates. These two
areas have different requirements regarding the DBS tech-
nique. For home sampling, it is necessary that the patient may
learn the technique by means of a short training session.
There are currently no devices for volumetric application
that are suitable to be used by a patient. In contrast, volu-
metric application of a DBS by a healthcare professional is a
viable route. These professionals can be adequately trained
and can acquire experience. This allows a wider choice of the
DBS techniques used in infants and neonates. In developing
a DBS method, it is important to define the scope: home
sampling or sampling in remote areas, influence of Hct, and
the need for converting blood concentration to plasma con-
centration. These requirements will be foremost in the
selection of the most suitable DBS method.
11 Conclusion
DBS sampling is increasingly used in TDM. Several
methods have been developed to correct for or minimize
the influence of Hct on the measurements. The studies
published on DBS sampling in TDM frequently show an
adequate analytical validation, but limited clinical valida-
tion. Promising developments are DPS using membranes
and Hct correction using the potassium concentration.
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